Effect of neurokinin 1 receptor antagonist in promoting chemotherapy sensitivity and reversing chemotherapy drug resistance in colorectal cancer

A receptor antagonist, neurokinin technology, applied in the field of medicine, can solve the problem that the molecular mechanism of NK-1R antagonist has not been well described.

Active Publication Date: 2021-07-23
中国人民解放军联勤保障部队第九〇三医院
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the molecular mechanisms underlying the efficacy of NK-1R antagonists in cancer cells are still not well described

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effect of neurokinin 1 receptor antagonist in promoting chemotherapy sensitivity and reversing chemotherapy drug resistance in colorectal cancer
  • Effect of neurokinin 1 receptor antagonist in promoting chemotherapy sensitivity and reversing chemotherapy drug resistance in colorectal cancer
  • Effect of neurokinin 1 receptor antagonist in promoting chemotherapy sensitivity and reversing chemotherapy drug resistance in colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] 1 Materials and methods

[0041] 1.1 Data Mining in Oncomine. Gene copy number and expression data for patients and cell lines were extracted from the Oncomine database (www.oncomine.org). TACR1 copy number level data were obtained from Reporter 02-072503625 of the Barretina CellLine 2 (GSE36138) dataset. TACR1 mRNA expression levels were obtained from Reporter 208048_at of the GarnettCellLine dataset. TAC1 copy number level data was obtained from Reporter07-097203463 of the Barretina CellLine2 (GSE36138) dataset. TAC1 mRNA expression levels were obtained from Reporter206552_s_at of the GarnettCellLine dataset.

[0042] 1.2 Cell culture. In the research of the present invention, HCT116 and SW620 cells were obtained from the First Affiliated Hospital of Zhejiang University, and HCT116 cells resistant to 5-FU (HCT116 / 5-FU) were obtained from Beijing Beina Chuanglian Biotechnology Research Institute. SW620 was cultured in DMEM (Life Technologies), and HCT116 and HCT11...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an effect of a neurokinin 1 receptor antagonist in promoting chemotherapy sensitivity and reversing chemotherapy drug resistance in colorectal cancer, in particular to a method for promoting the sensitivity of cancer chemotherapy in a subject or reversing the drug resistance of cancer chemotherapy in the subject. The method comprises the step of administering to the subject a therapeutically effective amount of an NK-1R antagonist. Furthermore, the invention relates to a pharmaceutical composition for treating colorectal cancer. The pharmaceutical composition is prepared from the NK-1R antagonist, a chemotherapeutic drug and an optional pharmaceutically acceptable carrier.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a method for promoting chemosensitivity and reversing chemoresistance in the treatment of colorectal cancer, and to a pharmaceutical product containing a neurokinin 1 receptor antagonist. Background technique [0002] Colorectal cancer (CRC) is the second and third most common cancer diagnosed in women and men, respectively, with an increasing mortality rate [1] . Since 1995, the incidence rate has increased by 2.2% per year, especially among young adults under the age of 50 [2] . Using current standard therapies, including surgery, chemotherapy, and radiation therapy, the 5-year relative survival rate for CRC patients is 65%, however, this drops to 12% for CRC patients with stage IV disease [3] . Therefore, understanding the pathogenesis of CRC and developing novel therapies represent an unmet clinical need in CRC patients. [0003] Substance P (Substance P, SP) is the first identif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K45/06A61P35/00
CPCA61P35/00A61K31/5377A61K31/4545A61K31/555A61K2300/00
Inventor 王喜付彩云邵罡程旭锐王凌菲蒙月明张奇瑜
Owner 中国人民解放军联勤保障部队第九〇三医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap